Clinical trial
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
NCT04187404 is registered in ClinicalTrials.gov with Enterome as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
- Lead sponsor
- Enterome
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- July 23, 2020
- Completion date
- October 2, 2024
- Enrollment
- 70 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.